Analysis of serum levels of B cell activating factor and soluble B cell activating factor receptor with disease activity in systemic lupus erythematosus
Article Sidebar
Main Article Content
Abstract
Background
Systemic lupus erythematosus (SLE) is caused by B-cell hyperactivity, which stimulates the production of autoantibodies, leading to the formation of immune complexes and resulting in tissue damage. Increased B-cell activation is associated with disease activity in SLE. The cytokine B-cell Activating Factor (BAFF) and its soluble BAFF receptor (sBAFF-R) play a crucial role in B-cell activation and survival. Their serum levels may serve as potential biomarkers for SLE severity. This study aimed to compare serum levels of BAFF and sBAFF-R between SLE patients with mild, moderate, and severe disease activity.
Methods
A cross-sectional study was conducted involving 33 female SLE patients. Subjects were divided into mild, moderate, and severe disease activity groups. Disease activity was assessed using Mexican Systemic Lupus Erythematosus Disease Activity Index (MEX-SLEDAI) scores. Serum BAFF and sBAFF-R levels were measured using ELISA. Data were analyzed using the Kruskal–Wallis and Mann-Whitney tests. A p-value < 0.05 was considered statistically significant.
Results
The median serum BAFF level in SLE patients was 0.51 ng/mL, and 4.66 ng/mL in sBAFF-R level.There was a statistically significant difference in serum BAFF and sBAFF-R levels between mild, moderate, and severe disease activity among SLE patients (p<0.0001).
Conclusion
Increased serum levels of BAFF and sBAFF-R may influence disease activity in SLE. Serum concentrations of BAFF and sBAFF-R were found to be associated with disease severity, including mild, moderate, and severe categories. These findings suggest that serum BAFF and sBAFF-R levels may serve as potential biomarkers for assessing SLE activity.
Article Details
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The journal allows the authors to hold the copyright without restrictions and allow the authors to retain publishing rights without restrictions.
How to Cite
References
1. Tian J, Zhang D, Yao X, Huang Y, Lu Q. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis 2023;82:351–6. doi:10.1136/ard-2022-223035.
2. Tanaka Y, O’Neill S, Li M, Tsai IC, Yang YW. Systemic lupus erythematosus: targeted literature review of the epidemiology, current treatment, and disease burden in the Asia Pacific region. Arthritis Care Res (Hoboken) 2022;74:187–98. doi:10.1002/acr.24431.
3. Barber MRW, Drenkard C, Falasinnu T, et al. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol 2021;17:515-32. doi: 10.1038/s41584-021-00668-1.
4. Parodis I, Stockfelt M, Sjöwall C. B cell therapy in systemic lupus erythematosus: from rationale to clinical practice. Front Med (Lausanne) 2020;7:370. doi: 10.3389/fmed.2020.00316.
5. Giordano D, Kuley R, Draves KE, Elkon KB, Giltiay NV, Clark EA. B cell activating factor (BAFF) from dendritic cells, monocytes and neutrophils is required for B cell maturation and autoantibody production in SLE like autoimmune disease. Front Immunol 2023;14:1115967. doi: 10.3389/fimmu.2023.1050528.
6. Du SW, Jacobs HM, Arkatkar T, Rawlings DJ, Samuel WJ. Integrated B cell, toll like, and BAFF receptor signals promote autoantibody production by transitional B cells. J Immunol 2019;201: 3258–68. doi:10.4049/jimmunol.1800393.
7. Perhimpunan Reumatologi Indonesia. Rekomendasi Perhimpunan Reumatologi Indonesia: diagnosis dan pengelolaan lupus eritematosus sistemik. Jakarta: Perhimpunan Reumatologi Indonesia; 2019.
8. Gergianaki I, Bortoluzzi A, Bertsias G. Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2018;32:188–205. doi:10.1016/j.berh.2018.09.004.
9. Uribe AG, Vilá LM, McGwin G Jr, Sanchez ML, Reveille JD, Alarcón GS. The systemic lupus activity measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. J Rheumatol 2004;31:1934–40.
10. Sari S, Cinar S, Yalcinkaya Y, et al. The relationship between serum A proliferation inducing ligand and B cell activating factor levels with disease activity and organ involvement in systemic lupus erythematosus. Lupus 2022;31:555–64. DOI: 10.1177/09612033221086123
11. Salazar Camarena DC, Ortiz Lazareno PC, Cruz A, et al. Association of BAFF, APRIL serum levels, BAFF R, TACI and BCMA expression on peripheral B cell subsets with clinical manifestations in systemic lupus erythematosus. Lupus 2016;25:582–92. doi: 10.1177/0961203315608254.
12. Salazar-Camarena DC, Palafox Sánchez CA, Cruz A, Marín Rosales M, Muñoz Valle JF. Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients. J Sci Rep 2020;10:6236. doi: 10.1038/s41598-020-63390-0.
13. Vincent FB, Kandane Rathnayake R, Koelmeyer R, et al. Analysis of serum B cell activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosus. Clin Transl Immunol 2019;8: e01062. doi: 10.1002/cti2.1047.
14. Vitri RY, Wachjudi RG, Ghassani NG, Hamijoyo L. Correlation of B cell activating factor levels and disease activity in systemic lupus erythematosus patients. Indian J Rheumatol 2021;1613–7. doi:10.4103/injr.injr_122_20.
15. Duan JH, Jiang Y, Mu H, Tang ZQ. Expression of BAFF and BR3 in patients with systemic lupus erythematosus. Braz J Med Biol Res 2016;49: e5252. doi: 10.1590/1414-431X20154853.
16. Zaki D, Ayoub NM, Mohammed ZAZ, Faramawy HH. Study of B cell activating factor (BAFF) and BAFF-R in systemic lupus erythematosus patients. Am J Med Med Sci 2019;9203–9. doi:10.5923/j.ajmms.20190906.06.
17. Zollars E, Bienkowska J, Czerkowicz J, et al. BAFF (B cell activating factor) transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year. Lupus Sci Med 2015;2:e000063. doi: 10.1136/lupus-2014-000063.
18. Marín Rosales M, Cruz A, Salazar Camarena DC, et al. High BAFF expression associated with active disease in systemic lupus erythematosus and relationship with rs9514828C>T polymorphism in TNFSF13B gene. Clin Exp Med 2019;19:183–90. doi: 10.1007/s10238-019-00549-8.
19. Durcan L, Petri M. Why targeted therapies are necessary for systemic lupus erythematosus. Lupus 2016;25:1070–9. doi: 10.1177/0961203316652489.
20. Fanouriakis A, Kostopoulou M, Andersen J, EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2023;83:15–29. doi: 10.1136/ard-2023-224762.
21. Roth DA, Thompson A, Tang Y, Hammer AE, Molta CT, Gordon D. Elevated BLyS levels in patients with systemic lupus erythematosus: associated factors and responses to belimumab. Lupus 2016;25:346–54. doi: 10.1177/0961203315604909.